Cardiology journal最新文献_第6页

Diagnostic value of soluble urokinase-type plasminogen activator receptor in patients with acute coronary syndrome: A systematic review and meta-analysis. 可溶性尿激酶型纤溶酶原激活物受体对急性冠状动脉综合征患者的诊断价值：系统综述和荟萃分析。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2023-09-29 DOI: 10.5603/cj.96228

Michal Pruc, Iwona Jannasz, Damian Swieczkowski, Grzegorz Procyk, Aleksandra Gasecka, Zubaid Rafique, Francesco Chirico, Nicola Luigi Bragazzi, Milosz J Jaguszewski, Jaroslaw Wysocki, Lukasz Szarpak

{"title":"Diagnostic value of soluble urokinase-type plasminogen activator receptor in patients with acute coronary syndrome: A systematic review and meta-analysis.","authors":"Michal Pruc, Iwona Jannasz, Damian Swieczkowski, Grzegorz Procyk, Aleksandra Gasecka, Zubaid Rafique, Francesco Chirico, Nicola Luigi Bragazzi, Milosz J Jaguszewski, Jaroslaw Wysocki, Lukasz Szarpak","doi":"10.5603/cj.96228","DOIUrl":"10.5603/cj.96228","url":null,"abstract":"Background: In contemporary clinical practice, there is an increasing need for new clinically relevant biomarkers potentially optimizing management strategies in patients with suspected acute coronary syndrome (ACS). This study aimed to determine the diagnostic utility of soluble urokinase-type plasminogen activator receptor (suPAR) levels in individuals with suspected ACS.Methods: A literature search was performed in Web of Science, PubMed, Scopus, and the Cochrane Central Register of Controlled Trials databases, for studies comparing suPAR levels among patients with and without ACS groups. The methodological quality of the included papers was assessed using the Newcastle-Ottawa Scale (NOS). A fixed-effects model was used if I² < 50%; otherwise, the random-effects model was performed.Results: Five studies with 3417 participants were included in the meta-analysis. Pooled analysis showed that mean suPAR levels in the ACS group were statistically significantly higher than in the control group (3.56 ± 1.38 vs. 2.78 ± 0.54 ng/mL, respectively; mean difference: 1.04; 95% confidence interval: 0.64-1.44; I² = 99%; p < 0.001).Conclusions: In the context of acute coronary syndrome, suPAR is a potential biomarker for the early identification of medical conditions in individuals who are being treated in emergency rooms.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41157403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are we at dawn of the drug-coated balloons era? Current evidence, future directions, and tasks of the newly established working group of the Association of Cardiovascular Interventions. 药物涂层球囊时代来临了吗？当前证据、未来方向以及心血管介入协会新成立工作组的任务。

Cardiology journal Pub Date : 2024-01-01 DOI: 10.5603/cj.98927

Sylwia Iwańczyk, Kamil Bujak, Rafał Wolny, Adam Janas, Miłosz Dziarmaga, Maksymilian P Opolski, Rafał Januszek, Adrian Włodarczak, Piotr Desperak, Piotr Niezgoda, Michał Kryjak, Mariusz Tomaniak, Zenon Huczek, Michał Hawranek, Bernardo Cortese, Wojciech Wańha

引用次数: 0

Quality of life in heart failure: New data, new drugs and devices. 心力衰竭患者的生活质量：新数据、新药物和设备。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2023-10-12 DOI: 10.5603/cj.92243

Katarzyna Major, Aleksandra Bodys-Pełka, Marcin Grabowski, Małgorzata Lelonek

引用次数: 0

Statins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients. 他汀类药物与胰腺癌风险:一项对2,797,186例患者的系统回顾和荟萃分析。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2022-04-04 DOI: 10.5603/CJ.a2022.0014

Eryka Karbowska, Damian Swieczkowski, Aleksandra Gasecka, Michal Pruc, Kamil Safiejko, Jerzy R Ladny, Tomasz Kopiec, Milosz J Jaguszewski, Krzysztof J Filipiak, Zubaid Rafique, Lukasz Szarpak

{"title":"Statins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients.","authors":"Eryka Karbowska, Damian Swieczkowski, Aleksandra Gasecka, Michal Pruc, Kamil Safiejko, Jerzy R Ladny, Tomasz Kopiec, Milosz J Jaguszewski, Krzysztof J Filipiak, Zubaid Rafique, Lukasz Szarpak","doi":"10.5603/CJ.a2022.0014","DOIUrl":"10.5603/CJ.a2022.0014","url":null,"abstract":"Background: Statin use in many studies is related to the improvement of a patients' condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective.Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI).Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72-0.96; I² = 84%; p = 0.01).Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46352304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bivalirudin versus heparin in contemporary percutaneous coronary interventions for patients with acute coronary syndrome: a systematic review and meta-analysis. 比伐鲁定与肝素在当代急性冠脉综合征患者经皮冠状动脉介入治疗中的应用:一项系统综述和荟萃分析。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2023-11-15 DOI: 10.5603/cj.90956

Junyan Zhang, Zhongxiu Chen, Duolao Wang, Chen Li, Fangbo Luo, Yong He

{"title":"Bivalirudin versus heparin in contemporary percutaneous coronary interventions for patients with acute coronary syndrome: a systematic review and meta-analysis.","authors":"Junyan Zhang, Zhongxiu Chen, Duolao Wang, Chen Li, Fangbo Luo, Yong He","doi":"10.5603/cj.90956","DOIUrl":"10.5603/cj.90956","url":null,"abstract":"Background: Bivalirudin is associated with fewer major bleeding events than heparin in patients undergoing percutaneous coronary intervention (PCI), but confounding effects of concomitant glycoprotein IIb/IIIa inhibitors, routine femoral artery access, and less potent effects of clopidogrel limits meaningful comparisons. The present study is a systematic review and meta-analysis to compare bivalirudin to heparin in contemporary practice.Methods: The Cochrane Library, PubMed, EMBASE, and Ovid MEDLINE databases were searched for relevant studies, including comparisons between bivalirudin and heparin in the current medical era from inception to December 23, 2021. Studies reporting incidences of major adverse cardiac events (MACE) and net adverse clinical events (NACE) in patients undergoing PCI and meeting the inclusion criteria were retained. Data extraction was performed by three independent reviewers.Results: The meta-analysis included 8 studies. Compared to heparin, bivalirudin during PCI was associated with a lower NACE risk, lower all-cause death, and similar MACE risk, with a pooled risk ratio of 0.82 (95% confidence interval [CI] 0.69-0.97, p = 0.02), 0.83 (95% CI 0.74-0.94, p = 0.002), and 0.93 (95% CI 0.78-1.10, p = 0.38), respectively. Moreover, the reduction in NACE was mainly attributed to reduced bleeding (22% reduction in the risk of major bleeding, 95% CI 0.63-0.97, p = 0.03).Conclusions: These findings suggest that bivalirudin use during PCI reduced the risk of NACE and all-cause death but did not reduce the risk of MACE compared with heparin use in PCI. More studies specifically designed for anticoagulation strategies and a personalized anticoagulation regimen to comprehensively balance bleeding and ischemia risks are required.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107593124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current understanding of Duchenne muscular dystrophy - a purported interview with a purported expert. 目前对杜兴氏肌肉萎缩症的认识--对所谓专家的访谈。

Cardiology journal Pub Date : 2024-01-01 DOI: 10.5603/cj.94330

Jarosław Meyer-Szary, Szymon Mikulski

引用次数: 0

Percutaneous transaxillary approach for balloon aortic valvuloplasty and complex percutaneous coronary intervention with Impella support. 经皮经腋窝方法进行球囊主动脉瓣成形术和有 Impella 支持的复杂经皮冠状动脉介入治疗。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2024-01-22 DOI: 10.5603/cj.96161

Jerzy Sacha, Krzysztof Krawczyk, Przemysław Lipski, Piotr Feusette, Marek Gierlotka

引用次数: 0

Electrophysiology lab efficiency using cryoballoon for pulmonary vein isolation in central and eastern Europe: A sub-analysis of the cryo global registry study. 中欧和东欧使用冷冻球囊进行肺静脉隔离的电生理学实验室效率：冷冻全球注册研究子分析。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2024-08-13 DOI: 10.5603/cj.98292

Csaba Földesi, Dejan Kojić, Adriana Sudzinova, Marcin Kuniewicz, Petr Neužil, Zoltan Csanadi, Martin Škamla, Martin Svetlošák, Janusz Romanek, Reece Holbrook, Martin Stefanic, Alicia Sale, Thomas R Holmes, Paweł Ptaszyński

{"title":"Electrophysiology lab efficiency using cryoballoon for pulmonary vein isolation in central and eastern Europe: A sub-analysis of the cryo global registry study.","authors":"Csaba Földesi, Dejan Kojić, Adriana Sudzinova, Marcin Kuniewicz, Petr Neužil, Zoltan Csanadi, Martin Škamla, Martin Svetlošák, Janusz Romanek, Reece Holbrook, Martin Stefanic, Alicia Sale, Thomas R Holmes, Paweł Ptaszyński","doi":"10.5603/cj.98292","DOIUrl":"10.5603/cj.98292","url":null,"abstract":"Background: Cryoballoon ablation for treatment of atrial fibrillation (AF) reduces procedure times, but limited data is available about its impact on electrophysiology (EP) lab efficiency in Central and Eastern Europe (CEE). Using CEE-specific procedure data, the present study modeled cryoballoon ablation procedures on EP lab resource consumption to improve efficiency.Methods: A discrete event simulation model was developed to assess EP efficiency with cryoballoon ablation. Model inputs were taken from CEE sites within the Cryo Global Registry, namely Czech Republic, Hungary, Poland, Serbia, and Slovakia. The main endpoints were percentage of days that resulted in overtime and percentage of days with time for one extra simple EP procedure. Use of the 'figure of 8' (Fo8) closure technique to reduce procedure time was also examined.Results: The mean lab occupancy time across all CEE sites was 133 ± 47 minutes (min: 104 minutes, max:181 minutes). Cryoballoon ablation in the base-case scenario resulted in 14.6% of days with overtime and 64.8% of days with time for an extra simple EP procedure. Use of the Fo8 closure technique enhanced these values to 5.5% and 85.3%, respectively. Model endpoints were most sensitive to changes in lab occupancy times and overtime start time.Conclusions: In this CEE-specific analysis of EP lab efficiency it was found that 3 cryoballoon ablation procedures could be performed in 1 lab day, leaving time for a 4th simple EP procedure on most days. As such, use cryoballoon ablation for PVI is an effective way to improve EP lab efficiency.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141972462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction. 静脉补铁改善了运动骨骼肌的能量代谢，对射血分数降低的男性心力衰竭患者的氧化应激或炎症没有影响。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2023-10-19 DOI: 10.5603/cj.97253

Marcin D Drozd, Michał Tkaczyszyn, Monika Kasztura, Kinga Węgrzynowska-Teodorczyk, Irena Flinta, Waldemar Banasiak, Piotr Ponikowski, Ewa A Jankowska

{"title":"Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction.","authors":"Marcin D Drozd, Michał Tkaczyszyn, Monika Kasztura, Kinga Węgrzynowska-Teodorczyk, Irena Flinta, Waldemar Banasiak, Piotr Ponikowski, Ewa A Jankowska","doi":"10.5603/cj.97253","DOIUrl":"10.5603/cj.97253","url":null,"abstract":"Background: Skeletal muscle dysfunction is a feature of heart failure (HF). Iron deficiency (ID) is prevalent in patients with HF associated with exercise intolerance and poor quality of life. Intravenous iron in iron deficient patients with HF has attenuated HF symptoms, however the pathomechanisms remain unclear. The aim of study was to assess whether intravenous iron supplementation as compared to placebo improves energy metabolism of skeletal muscles in patients with HF.Methods: Men with heart failure with reduced ejection fraction (HFrEF) and ID were randomised in 1:1 ratio to either intravenous ferric carboxymaltose (IV FCM) or placebo. In vivo reduction of lactates by exercising skeletal muscles of forearm was analyzed. A change in lactate production between week 0 and 24 was considered as a primary endpoint of the study.Results: There were two study arms: the placebo and the IV FCM (12 and 11 male patients with HFrEF). At baseline, there were no differences between these two study arms. IV FCM therapy as compared to placebo reduced the exertional production of lactates in exercising skeletal muscles. These effects were accompanied by a significant increase in both serum ferritin and transferrin saturation in the IV FCM arm which was not demonstrated in the placebo arm.Conclusions: Intravenous iron supplementation in iron deficient men with HFrEF improves the functioning of skeletal muscles via an improvement in energy metabolism in exercising skeletal muscles, limiting the contribution of anaerobic reactions generating ATP as reflected by a lower in vivo lactate production in exercising muscles in patients with repleted iron stores.","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in myocarditis management in the light of the latest research and recent guidelines of the European Society of Cardiology. 根据最新研究成果和欧洲心脏病学会的最新指导方针，推进心肌炎的治疗。

Cardiology journal Pub Date : 2024-01-01 Epub Date: 2024-01-22 DOI: 10.5603/cj.95175

Aleksandra Chabior, Agata Tymińska, Agnieszka Pawlak, Andrea Giordani, Alida Caforio, Marcin Grabowski, Krzysztof Ozierański

引用次数: 0